🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating globally, with data suggesting more than 82 million new cases per year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the context of growing infection rates, the spread of superbugs and the highly restricted treatment choices at this time.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts anticipate that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is employed against UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to develop it.

“This authorization marks a major breakthrough in the treatment of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Outcomes and Global Access

According to results detailed in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which combines an injection and a pill. The research enrolled hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors treating patients have shared optimism. The availability of a easy-to-administer therapy such as this is described as a "critical tool" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for people and to stop the proliferation of extremely resistant gonorrhoea globally.